VRS-317 Phase 1 Study Explores Long-Acting Growth Hormone Deficiency Treatment

Adult Growth Hormone Deficiency (GHD) is a chronic condition resulting from insufficient growth hormone production, leading to various metabolic and physiological impairments. Current treatments often necessitate frequent, sometimes daily, injections, which can significantly impact patient adherence and quality of life. This Phase 1 study aimed to assess the safety, tolerability, and pharmacodynamics of a novel, long-acting growth hormone analog, VRS-317, to potentially reduce the burden of frequent dosing.

The study was designed to characterize the safety and tolerability profile of VRS-317 across its ascending dose range, with the objective of identifying any dose-limiting toxicities or significant adverse events. Pharmacokinetic analysis aimed to describe the absorption, distribution, metabolism, and excretion of VRS-317, including its half-life, to understand its potential for sustained action. Pharmacodynamic assessments were intended to quantify the biological activity of VRS-317 by measuring changes in IGF-I (insulin-like growth factor-1) and IGFBP-3 (IGF binding protein-3) levels from baseline, which are key indicators of growth hormone action. The primary objective was to determine if a single dose of VRS-317 could sustain IGF-I levels within the normal range for adult GHD patients for up to one month, a critical step towards reducing injection frequency. Additionally, bone turnover markers, such as bone alkaline phosphatase, were measured to assess the impact of VRS-317 on bone health, a significant concern in GHD management.